替罗非班与双抗治疗进展性脑卒中的疗效对比

Comparison Between Tirofiban and Dual Antiplatelet Therapy in Treating Progressive Stroke

目的对进展性脑卒中患者分别施以替罗非班及双抗治疗,比对效果。方法本次研究选取2018年1月—2019年12月期间来医院进行治疗的68例进展性脑卒中患者,按照用药的不同进行分组,给予双抗治疗的34例患者为对照组,先给予替罗非班再给予双抗治疗的34例患者为观察组,比较两组疗效。结果就治疗总有效率比较结果来看,观察组显示出明显优势,与对照组差异有统计学意义(P<0.05)。就两组NIHSS评分及BI指数比较结果而言,治疗前组间差异无统计学意义(P>0.05),治疗后组间差异增大,且观察组情况更优,与对照组比较差异有统计学意义(P<0.05)。结论经比较,替罗非班是一种值得推荐的治疗药物,临床效果更佳。

Objective Patients with progressive stroke were treated with tirofiban and dual antiplatelet therapy,and the results were compared.Methods From January 2018 to December 2019,68 patients were selected with progressive stroke,grouped according to different medication.34 patients in control group were treated with dual antiplatelet therapy,34 patients in observation group were administered first with tirofiban then dual antiplatelet therapy,the effect was compared between two groups.Results Compared with the control group,the observation group showed significance statistically(P<0.05).Two groups in NIHSS score and BI index had no significance difference before treatment(P>0.05),and the observation group was better after treatment(P<0.05).Conclusion By comparison,tirofeban is a recommended drug with better clinical effect.